Cable Viewer

Currently released so far... 11218 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/06
1986/05
1987/06
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/12
1993/10
1996/11
1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/11 2002/12
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
AF AM AJ ASEC AS AFIN AMGT AU AE AR ABLD AG AY AORC ASIG AEMR APER AMBASSADOR ASEAN AA AL ASUP ABUD AMED AX APECO AID AUC ASECKFRDCVISKIRFPHUMSMIGEG ADANA AFFAIRS AND AN ADCO ARM ATRN AECL AADP ACOA APEC AGRICULTURE ACS ADPM ASCH AMEX ACAO ANET AODE ARF ACBAQ APCS AMG AQ AMCHAMS AORG AGAO ADM AFSI AFSN AINF AIT ASEX AO ATFN AROC AFGHANISTAN AFU AER ALOW AC AZ AVERY AGMT
BA BRUSSELS BR BL BM BEXP BH BTIO BIDEN BO BT BC BU BY BX BG BK BF BBSR BMGT BTIU BE BD BWC BB BP BILAT
CA CW CH CO CONDOLEEZZA CR CASC CSW CVIS CPAS CMGT CS CI CU CJUS CY CDG CE CG CBW COUNTER CN CKGR COUNTERTERRORISM CODEL CWC CJAN CIA CD CLINTON CT CARSON CONS CB CM CFED CLMT CROS CNARC CIDA CBSA CIC CEUDA CHR CITT CAC CACM CVR CDC CAPC COPUOS CBC CBE COM CDB CAN COE COUNTRY CLEARANCE CACS CF CL CIS CTM CV CICTE
DR DEA DA DOMESTIC DHS DAO DCM DEPT DTRA DPRK DEFENSE DE DJ DISENGAGEMENT DOD DEAX DOE DK DS
ENRG EPET ETRD EFIS ECON EK EAID EUN ES EFIN EWWT ECIN EINV ETTC EAGR EC ELAB ECPS EN EG ELTN EAIR EPA ER EI EU EZ ET EIND EINVECONSENVCSJA ECONOMICS EXTERNAL ELN ELECTIONS EMIN EINN EFINECONCS ETRDEINVECINPGOVCS ENIV ECUN EINT ENGR ENNP EUR EAP EEPET ETRDEINVTINTCS ENVI EFTA ETRO ESENV ECINECONCS ENVR ECONOMY ECONOMIC EUMEM EAIDS ETRA ETRN EUREM EFIM EIAR EXIM ERD EAIG ETRC EXBS EINVEFIN ECIP EINDETRD EUC EREL ECA ENERG ENGY ECONCS EINVETC ECONEFIN ESA ETC ETRDECONWTOCS EUNCH
FI FR FREEDOM FTAA FARC FAO FJ FMLN FBI FOR FTA FOREIGN FINANCE FO FISO FDA FAC FOI FM FINR
GG GT GM GV GH GOI GA GTIP GR GZ GE GCC GY GOV GAERC GANGS GL GLOBAL GERARD GF GAZA GTMO
HO HA HK HUMAN HU HR HILLARY HSTC HUMOR HEBRON HI HURI HYMPSK
IWC IR IZ ICAO IV IRS IC IS IT IZPREL IRAQI IO IN IAEA ID ITPHUM ITPGOV ITALIAN IPR INRB IMO ITALY ICRC INTERPOL IQ ICTY INTELSAT IEFIN IA INR IRC IACI ITRA IL ICJ INTERNAL ISRAELI INMARSAT ITU ILC IBRD IMF ILO IDP ITF IBET IGAD IEA IAHRC ICTR IDA IIP INRA INRO IRAJ IF
JP JA JO JOSEPH JOHNNIE JM JUS JAMES
KSCA KNNP KIPR KOLY KS KPAO KMPI KDEM KZ KG KJUS KRVC KICC KTIA KISL KTIP KCRM KWMN KMDR KVPR KV KHLS KU KTFN KIRF KR KPKO KTDB KIRC KGHG KFRD KCOR KE KSUM KPAL KSEP KSTC KGIC KOMC KFLO KAWC KUNR KNPP KIDE KNEI KBIO KPRP KN KWBG KMCA KCIP KTEX KGIT KNSD KCFE KLIG KFLU KBCT KOMS KBTS KACT KCRS KGCC KDRG KWMM KAWK KHIV KSPR KRAD KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KOCI KSTH KPAI KHSA KTLA KO KFSC KVIR KX KFTFN KHDP KPLS KSAF KMFO KRCM KCSY KSAC KPWR KTRD KID KWNM KMRS KICA KRIM KSEO KPOA KCHG KREC KOM KRGY KCMR KSCI KFIN KVRP KPAONZ KCGC KNAR KMOC KWAC KMIG KSEC KIFR KDEMAF KNUC KPIN KPRV KBTR KERG KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KNUP KTER KDDG KPAK KREL KCOM KNNPMNUC KRFD KHUM KDEV KCFC KWWMN KTBT KWMNCS KJUST
LE LY LU LTTE LI LO LH LG LAB LA LABOR LOG LT
MNUC MARR MASS MCAP MIL MO MOPS MU MX MEPI MR MDC MPOS MEETINGS MD MTCRE MK MUCN MY MASC MRCRE ML MA MEPP MAR MAPP MP MT MAS MTS MLS MI MERCOSUR MC MV MEDIA MILI MEPN MG MW MIK MTCR MARAD MZ MOPPS MAPS MCC MASSMNUC MQADHAFI MTRE
NZ NL NATO NO NAFTA NDP NIPP NP NS NPT NU NI NATIONAL NPG NGO NG NK NA NSSP NRR NSG NSC NPA NORAD NT NW NEW NH NSF NV NR NE NSFO NC NAR NASA NZUS
OTRA OEXC OIIP OVIP OAS OREP OSCE OPRC ODIP OSAC OPIC OPDC OFDP OIE OECD OPCW OVP OPAD OFDA OIC OSCI OMIG OBSP ON OCS OCII OHUM OTR OFFICIALS
PGOV PARM PREL PHUM PTER PINR PK PREF POL PINS PSOE PAK PBTS PHSA PAO PM PF PNAT PE POLITICS PARMS PBIO PSI POLINT POLITICAL PARTIES PL PA PROP PO PGOVLO PORG PGOVE PLN PINF PRELP PAS PPA PRGOV PUNE PG PALESTINIAN POLICY PROG PDEM PREFA PDOV PCI PRAM PTBS PSA POSTS PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PGIV PHUMPGOV PCUL PSEPC PREO PAHO PMIL PNG PP PS PHUH PEPR PINT PU PECON POGOV PINL PKFK PY PFOR PHALANAGE PARTY PMAR PHUMPREL PHUS PRL PGOC PNR PGGV PROV PTERE PGOF PHUMBA PEL POV
QA
RICE RUPREL RU RS RIGHTS RO RW RSP RP REACTION REPORT RCMP RSO RF RFE RM RIGHTSPOLMIL ROBERT REGION
SENV SCUL SNAR SOCI SW SMIG SP SZ SA SY SENVKGHG SU SF SAN SR SO SHUM SYR SAARC SL SI SNARCS SWE SN SARS SPCE SNARIZ SCRS SC SIPDIS SEN SNARN SPCVIS STEINBERG SG SIPRS SH SOFA SANC SK ST SEVN
TPHY TW TC TX TU TI TN TS TT TRGY TO TH TBIO TSPL TIP TP TERRORISM TURKEY TSPA TD TZ TFIN TNGD TINT THPY TBID TF TL TV TAGS TK TR TRSY
UNSC UZ USEU US UN UK UP USTR UNGA UNMIK USUN UNESCO UNHRC UY UNO UG UNDC UAE UNAUS UNDESCO UNHCR UNEP UNCHC UNFICYP UNCHR USNC UNIDROIT UNCSD UNDP UNC UNODC USOAS UNPUOS UNCND USPS UNICEF UV UNCHS UNVIE UE USAID
VZ VT VE VTPREL VM VI VAT VN
WS WTRO WITH WHO WTRQ WBG WI WTO WHA WMD WMO WIPO WHTI WFP WB WWARD WA WEU WZ
XM XV XF XR XA XK XH XL XS XG XW XY XE XT XD XZ XX XTAG XQ XB XU XI XC
YM YI YMCS YE
ZR ZI ZANU ZU ZO ZP ZB ZL ZK ZF ZEALAND ZN ZA ZOELLICK ZJ

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06WELLINGTON475, INDUSTRY SEES HIGHER COSTS UNDER NEW ZEALAND-AUSTRALIA

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06WELLINGTON475.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06WELLINGTON475 | 2006-06-21 23:11 | 2011-04-28 00:12 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Wellington

`

    VZCZCXRO6701
    RR RUEHNZ
    DE RUEHWL #0475/01 1722314
    ZNR UUUUU ZZH
    R 212314Z JUN 06
    FM AMEMBASSY WELLINGTON
    TO RUEHC/SECSTATE WASHDC 2921
    INFO RUCPDOC/USDOC WASHDC 0062
    RUEHNZ/AMCONSUL AUCKLAND 0791
    RUEHBY/AMEMBASSY CANBERRA 4458
    RUEHDN/AMCONSUL SYDNEY 0448

` `

    UNCLAS SECTION 01 OF 02 WELLINGTON 000475

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS USTR-JJENSEN
    STATE PASS FDA FOR OFFICE OF INTERNATIONAL PROGRAMS
    STATE FOR EAP/ANP-DRICCI AND EB/TPP/BTA/ANA-MBGOODMAN
    COMMERCE FOR ABENAISSA/4530/ITA/MAC/AP/OSAO
    SYDNEY FOR CS

    E.O. 12958: N/A
    TAGS: ETRD ECON NZ
    SUBJECT: INDUSTRY SEES HIGHER COSTS UNDER NEW ZEALAND-AUSTRALIA
    REGULATORY AGENCY

    REF: (A) 05 WELLINGTON 119; (B) 04 WELLINGTON 596

    ¶1. (SBU) Begin summary:  Proposed rules for a new Australian-New
    Zealand regulatory agency for therapeutic products will make it
    costlier for U.S. makers of medical devices and complementary
    medicines to operate in New Zealand, according to the manufacturers'
    representatives.  They contend the proposed rules, issued May 23,
    would drive many of their products out of New Zealand.  In contrast,
    the pharmaceutical industry expects the agency would expedite the
    process for obtaining marketing approval for medicines and would
    save the industry in regulatory costs.  Its support of the agency,
    however, hinges on the New Zealand government continuing to allow
    direct-to-consumer advertising of prescription drugs, which is not
    allowed in Australia.  Meanwhile, the government does not yet have
    enough political support to pass the legislation necessary to set up
    the agency.  End summary.

    ¶2. (U) Australia and New Zealand signed an agreement in December
    2003 to provide unified regulation of prescription pharmaceuticals
    as well as therapeutic goods that have been virtually unregulated in
    New Zealand, including medical devices, over-the-counter medicines,
    dietary and nutritional supplements, and cosmetics and toiletries
    (ref B).  The proposed agency -- the Australia New Zealand
    Therapeutic Products Authority -- would replace the Australian
    Therapeutic Goods Administration (TGA) and the New Zealand Medicines
    and Medical Devices Safety Authority (Medsafe).  The deadline for
    public submissions on the draft rules is August 15.  The New Zealand
    government is hoping to introduce legislation in July to establish
    the agency and open the agency's doors in the second half of 2007.

    ¶3. (SBU) The agency's opening has been delayed a number of times
    previously (ref A), and passage of the implementing legislation is
    far from certain.  The Labour-led New
    Zealand government lacks the votes in Parliament to pass the
    legislation on its own and has no support yet from any other party.
    Some opponents are concerned about Australia's possible dominance of
    the agency, and others are worried that it would mean higher costs
    for industry and consumers in New Zealand.  Proponents say that New
    Zealand's participation in the joint agency would cost less than if
    it tried on its own to extend its regulatory authority to devices
    and other non-drug health products.

    Medical devices, complementary medicines
    ----------------------------------------
    ¶4. (SBU) Under the proposed rules, the agency would require licenses
    for all therapeutic goods and recover all its regulatory costs
    through fees and charges.  That would be particularly burdensome for
    New Zealand's medical device and complementary medicine sectors,
    which have not been required to obtain pre-market approval for their
    products and pay no licensing or other regulatory fees.  While the
    draft rules provide for a three-year transition period for product
    licenses to be obtained, industry representatives expect the fees to
    be so high that they will have to seek cheaper sources -- outside
    the United States -- for medical devices and complementary
    medicines.  They expect the fees to be similar to those already
    charged in Australia, which has a population and market roughly five
    times as large as New Zealand's.  They predict the compliance costs
    would force many smaller distributors and importers out of business
    in New Zealand.

    ¶5. (SBU) The draft rules also provide that the agency would conduct
    all conformity assessments for medical devices, including audits of
    manufacturers and testing of products to ensure they meet relevant
    standards, which also would increase the sector's costs.  Medical
    device representatives noted that the proposed agency would accept
    European certification, but not U.S. Food and Drug Administration
    certification.  As one representative said, that points to the need
    for a mutual recognition agreement between Australia and the United
    States, which presumably would enable the joint agency to accept FDA
    certification.

    ¶6. (SBU) The industry representatives said they support the agency
    in principle, recognizing the need for regulation of their products
    to ensure public safety.  However, they were disappointed that their
    years of consultations with the government about their concerns
    regarding a new regulatory regime were not reflected in the
    proposal.  They had hoped that the government at least would set
    fees according to the size of the product's market.

    Prescription drugs
    ------------------
    ¶7. (SBU) On the other hand, the pharmaceutical industry sees the

    WELLINGTON 00000475  002 OF 002

    joint agency as an improvement over New Zealand's existing small and
    overtaxed regulatory regime, in which obtaining marketing approval
    for prescription medicines can take more than three years.  The
    agency also could represent a cost-savings by providing a single
    point of entry for both markets, as opposed to requiring a product
    license in each country.  The industry is concerned, however, about
    whether labeling rules and other such requirements could be met
    within three years.  It is advocating a five-year transition period.

    ¶8. (SBU) The drug industry also says it will withdraw support of the
    agency if the New Zealand government uses it as an excuse to ban
    direct-to-consumer advertising (DTCA), which some firms have
    employed to boost sales of unsubsidized medicines in New Zealand's
    tightly restricted market.  Australia allows only disease-based,
    awareness-building advertising, while New Zealand is the only
    country in the world besides the United States that allows the
    pharmaceutical industry to promote its products directly to the
    public.  (The government is reviewing its policy on
    direct-to-consumer advertising of prescription medicines, in
    preparation for drafting new legislation on the regulation of DTCA.
    Such legislation is necessary because the law that would enable New
    Zealand to participate in the joint agency also would repeal the
    Medicines Act 1981, which allows DTCA.)

    Comment
    -------
    ¶9. (SBU) The joint agency's higher regulatory costs could lead to a
    decline in sales of U.S. medical devices and other therapeutic
    products in New Zealand.  Failure to recognize FDA certification
    also would add a discriminatory barrier to U.S. medical devices.
    While the need for improving regulation of therapeutic products in
    New Zealand should be acknowledged, post suggests these concerns be
    raised in the Trade and Investment Framework Agreement talks with
    New Zealand scheduled for July 27.

    MCCORMICK

`